Latest Partnerships News

FortifAI Limited reported a 51% revenue decline but a 70% reduction in net loss for H1 FY26, alongside completing a major AI technology acquisition and securing $5 million in fresh capital.

First Graphene Limited reported a strong 53% revenue increase driven by new industrial applications, yet posted a $3.35 million net loss influenced by non-cash finance costs. The company’s recent $3.5 million capital raise positions it to focus on commercial expansion without further funding.

NEXTDC has reported a robust first half of FY26, with strong revenue and earnings growth underpinned by a surging forward order book and expanded capital expenditure plans.

betr Entertainment has extended its NAB facility agreement maturity to July 2027, reinforcing its financial flexibility and growth ambitions. This move underscores a strong partnership with NAB amid betr’s evolving wagering business.

EcoGraf Limited has completed a comprehensive update to its Bankable Feasibility Study for the Epanko Graphite Project, confirming robust financials and a production increase to 73,000 tonnes per annum. The study underpins advanced project financing and highlights significant expansion potential amid rising global graphite demand.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

Oliver’s Real Food Limited has reported a statutory net profit after tax of $995,000 for the half-year ended December 2025, marking a $1.82 million turnaround from the previous loss. This improvement comes despite a 6.5% revenue decline, driven by strategic store closures and disciplined cost management.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.

Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.